| 000 | 01891 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517125901.0 | ||
| 264 | 0 | _c20170814 | |
| 008 | 201708s 0 0 eng d | ||
| 022 | _a1464-3391 | ||
| 024 | 7 |
_a10.1016/j.bmc.2016.11.032 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKošak, Urban | |
| 245 | 0 | 0 |
_aN-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents. _h[electronic resource] |
| 260 |
_bBioorganic & medicinal chemistry _c01 2017 |
||
| 300 |
_a633-645 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAlzheimer Disease _xdrug therapy |
| 650 | 0 | 4 |
_aAmyloid beta-Peptides _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aButyrylcholinesterase _xmetabolism |
| 650 | 0 | 4 |
_aCell Death _xdrug effects |
| 650 | 0 | 4 | _aCell Line |
| 650 | 0 | 4 |
_aCholinesterase Inhibitors _xchemical synthesis |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMolecular Structure |
| 650 | 0 | 4 |
_aMonoamine Oxidase _xmetabolism |
| 650 | 0 | 4 |
_aMonoamine Oxidase Inhibitors _xchemical synthesis |
| 650 | 0 | 4 |
_aNaphthalenes _xchemical synthesis |
| 650 | 0 | 4 |
_aPeptide Fragments _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPiperidines _xchemical synthesis |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 650 | 0 | 4 |
_aSulfonamides _xchemical synthesis |
| 700 | 1 | _aKnez, Damijan | |
| 700 | 1 | _aCoquelle, Nicolas | |
| 700 | 1 | _aBrus, Boris | |
| 700 | 1 | _aPišlar, Anja | |
| 700 | 1 | _aNachon, Florian | |
| 700 | 1 | _aBrazzolotto, Xavier | |
| 700 | 1 | _aKos, Janko | |
| 700 | 1 | _aColletier, Jacques-Philippe | |
| 700 | 1 | _aGobec, Stanislav | |
| 773 | 0 |
_tBioorganic & medicinal chemistry _gvol. 25 _gno. 2 _gp. 633-645 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bmc.2016.11.032 _zAvailable from publisher's website |
| 999 |
_c26658671 _d26658671 |
||